JP2008501741A - 多層制御放出性メチルフェニデートペレット - Google Patents
多層制御放出性メチルフェニデートペレット Download PDFInfo
- Publication number
- JP2008501741A JP2008501741A JP2007526245A JP2007526245A JP2008501741A JP 2008501741 A JP2008501741 A JP 2008501741A JP 2007526245 A JP2007526245 A JP 2007526245A JP 2007526245 A JP2007526245 A JP 2007526245A JP 2008501741 A JP2008501741 A JP 2008501741A
- Authority
- JP
- Japan
- Prior art keywords
- methylphenidate
- controlled release
- layer
- film
- pellet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 title claims abstract description 117
- 229960001344 methylphenidate Drugs 0.000 title claims abstract description 117
- 239000008188 pellet Substances 0.000 title claims abstract description 81
- 238000013270 controlled release Methods 0.000 title claims abstract description 37
- 239000010410 layer Substances 0.000 claims abstract description 92
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 38
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 38
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 38
- 239000007853 buffer solution Substances 0.000 claims abstract description 20
- 239000011241 protective layer Substances 0.000 claims abstract description 18
- 239000011248 coating agent Substances 0.000 claims abstract description 16
- 238000000576 coating method Methods 0.000 claims abstract description 16
- 239000000463 material Substances 0.000 claims description 37
- 239000004014 plasticizer Substances 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 26
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 20
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 18
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 claims description 15
- 229960001033 methylphenidate hydrochloride Drugs 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000004471 Glycine Substances 0.000 claims description 9
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 9
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 9
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical group O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 239000000049 pigment Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 239000001488 sodium phosphate Substances 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 3
- 239000004408 titanium dioxide Substances 0.000 claims description 3
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 2
- 235000019800 disodium phosphate Nutrition 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 claims 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims 1
- 235000019796 monopotassium phosphate Nutrition 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 235000021317 phosphate Nutrition 0.000 claims 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims 1
- 238000013268 sustained release Methods 0.000 abstract description 10
- 239000012730 sustained-release form Substances 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract description 6
- 230000003628 erosive effect Effects 0.000 abstract description 2
- 239000006185 dispersion Substances 0.000 description 10
- 230000002378 acidificating effect Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 229960004106 citric acid Drugs 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- -1 for example Chemical class 0.000 description 5
- 238000009472 formulation Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 229960002303 citric acid monohydrate Drugs 0.000 description 2
- 238000004581 coalescence Methods 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- DZGUJOWBVDZNNF-UHFFFAOYSA-N azanium;2-methylprop-2-enoate Chemical compound [NH4+].CC(=C)C([O-])=O DZGUJOWBVDZNNF-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000004682 monohydrates Chemical group 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- INGSNVSERUZOAK-UHFFFAOYSA-N ritalinic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)C1CCCCN1 INGSNVSERUZOAK-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP200401412 | 2004-06-10 | ||
| ES200401412A ES2261006B1 (es) | 2004-06-10 | 2004-06-10 | Pellet multicapa de liberacion controlada de metilfenidato. |
| PCT/EP2005/005874 WO2005120468A1 (en) | 2004-06-10 | 2005-06-01 | Multi-layered controlled-release methylphenidate pellet |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008501741A true JP2008501741A (ja) | 2008-01-24 |
| JP2008501741A6 JP2008501741A6 (ja) | 2008-05-29 |
| JP2008501741A5 JP2008501741A5 (enExample) | 2008-07-10 |
Family
ID=34969228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007526245A Withdrawn JP2008501741A (ja) | 2004-06-10 | 2005-06-01 | 多層制御放出性メチルフェニデートペレット |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080069872A1 (enExample) |
| EP (1) | EP1753410A1 (enExample) |
| JP (1) | JP2008501741A (enExample) |
| CA (1) | CA2566497A1 (enExample) |
| ES (1) | ES2261006B1 (enExample) |
| IL (1) | IL179338A0 (enExample) |
| WO (1) | WO2005120468A1 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012508228A (ja) * | 2008-11-07 | 2012-04-05 | サムヤン コーポレイション | メチルフェニデートの放出制御用薬剤学的組成物 |
| JP2013523804A (ja) * | 2010-04-07 | 2013-06-17 | ルピン・リミテッド | タペンタドールの制御放出医薬組成物 |
| KR101334947B1 (ko) * | 2011-11-28 | 2013-11-29 | 이승우 | 서방성 정제 및 그 제조방법 |
| JP2017128614A (ja) * | 2011-03-23 | 2017-07-27 | アイアンショア ファーマシューティカルズ アンド ディベロップメント， インコーポレイテッド | 注意欠陥障害の処置のための方法および組成物 |
| JP2017532363A (ja) * | 2014-10-31 | 2017-11-02 | パーデュー ファーマ | 特に注意欠陥障害の治療のための方法および組成物 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101288659B (zh) * | 2007-04-18 | 2014-06-18 | 王雷波 | 一种胃内漂浮型微丸及其制备方法 |
| EP2044932A1 (en) | 2007-10-04 | 2009-04-08 | Laboratorios del Dr. Esteve S.A. | Mechanical protective layer for solid dosage forms |
| ES2717469T3 (es) | 2012-08-15 | 2019-06-21 | Tris Pharma Inc | Comprimido masticable de metilfenidato de liberación prolongada |
| TWI634909B (zh) * | 2015-08-13 | 2018-09-11 | 生達化學製藥股份有限公司 | Long-acting sustained-release medicine composition and preparation method thereof |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| CN111557929B (zh) * | 2020-05-15 | 2021-12-07 | 河南中帅医药科技股份有限公司 | 一种盐酸右哌甲酯多重释放制剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5395626A (en) * | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
| US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| DE69920689T2 (de) * | 1998-06-03 | 2005-02-24 | Alza Corp., Mountain View | Vorrichtungen zum Aufrechterhalten eines gewünschten therapeutischen Medikamenteneffekts über einen verlängerten Therapiezeitraum |
| US6419960B1 (en) * | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| US6562375B1 (en) * | 1999-08-04 | 2003-05-13 | Yamanouchi Pharmaceuticals, Co., Ltd. | Stable pharmaceutical composition for oral use |
| US6344215B1 (en) | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
-
2004
- 2004-06-10 ES ES200401412A patent/ES2261006B1/es not_active Expired - Fee Related
-
2005
- 2005-06-01 CA CA002566497A patent/CA2566497A1/en not_active Abandoned
- 2005-06-01 JP JP2007526245A patent/JP2008501741A/ja not_active Withdrawn
- 2005-06-01 US US11/628,965 patent/US20080069872A1/en not_active Abandoned
- 2005-06-01 EP EP05746963A patent/EP1753410A1/en not_active Withdrawn
- 2005-06-01 WO PCT/EP2005/005874 patent/WO2005120468A1/en not_active Ceased
-
2006
- 2006-11-16 IL IL179338A patent/IL179338A0/en unknown
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012508228A (ja) * | 2008-11-07 | 2012-04-05 | サムヤン コーポレイション | メチルフェニデートの放出制御用薬剤学的組成物 |
| JP2015083599A (ja) * | 2008-11-07 | 2015-04-30 | サムヤン バイオファーマシューティカルズ コーポレイション | メチルフェニデートの放出制御用薬剤学的組成物 |
| JP2013523804A (ja) * | 2010-04-07 | 2013-06-17 | ルピン・リミテッド | タペンタドールの制御放出医薬組成物 |
| JP2017128614A (ja) * | 2011-03-23 | 2017-07-27 | アイアンショア ファーマシューティカルズ アンド ディベロップメント， インコーポレイテッド | 注意欠陥障害の処置のための方法および組成物 |
| KR101334947B1 (ko) * | 2011-11-28 | 2013-11-29 | 이승우 | 서방성 정제 및 그 제조방법 |
| JP2017532363A (ja) * | 2014-10-31 | 2017-11-02 | パーデュー ファーマ | 特に注意欠陥障害の治療のための方法および組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005120468A1 (en) | 2005-12-22 |
| EP1753410A1 (en) | 2007-02-21 |
| IL179338A0 (en) | 2007-03-08 |
| ES2261006A1 (es) | 2006-11-01 |
| US20080069872A1 (en) | 2008-03-20 |
| CA2566497A1 (en) | 2005-12-22 |
| ES2261006B1 (es) | 2007-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8747898B2 (en) | Controlled release oral dosage form | |
| AU2007211091B8 (en) | Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids | |
| JP4991072B2 (ja) | 時限拍動性薬物送達システム | |
| US6589553B2 (en) | Controlled release oral dosage form | |
| CA2426883C (en) | Methylphenidate modified release formulations | |
| CA2884901C (en) | Timed, pulsatile release systems | |
| US5122384A (en) | Oral once-per-day organic nitrate formulation which does not induce tolerance | |
| JP2002527468A (ja) | 脈動用量薬剤経口送達システム | |
| US20070270443A1 (en) | Methods and compositions for the treatment of viral infections | |
| CA2686094A1 (en) | Manufacturing method of a semiconductor element | |
| JP2008501741A6 (ja) | 多層制御放出性メチルフェニデートペレット | |
| JP2008501741A (ja) | 多層制御放出性メチルフェニデートペレット | |
| EP1748764B1 (en) | An amine drug-containing slow-release granule preparation based on particles with a coating layer and the corresponding method of production | |
| WO2007097770A1 (en) | Metoprolol succinate e.r. tablets and methods for their preparation | |
| US20030035840A1 (en) | Controlled release oral dosage form | |
| CN101478958A (zh) | 包含哌啶烷醇和减充血剂的组合的药物组合物 | |
| CA2433915C (en) | Improved controlled release oral dosage form | |
| AU2013204408B2 (en) | Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids | |
| ZA200701554B (en) | Sustained release pharmaceutical particulate compositio comprising venlafaxine | |
| MX2008004774A (en) | Enteric soft capsule comprising valproic acid | |
| AU2002253907A1 (en) | Improved controlled release oral dosage form |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080522 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080522 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20110117 |